Merck & Co squares up to Roche with Keytruda data in triple-...

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good

Merck builds case for six-week Keytruda dosing as FDA starts...

Immuno-oncology latecomer GSK shows off PD-1 drug data

BMS gets an important win for Opdivo combination in kidney c...

Epsilogen licenses first-in-class IgE ovarian cancer drug

BMS eyes August FDA verdict for Opdivo/Yervoy in first-line ...